Pharmacokinetics of platinum after oral or intravenous cisplatin: A phase 1 study in 32 adult patients

Cancer Chemotherapy and Pharmacology

Volumn 55, Issue 1, 2005, Pages 55-60

  Urien, Saik ^a   Brain, Etienne ^a   Bugat, Roland ^b   Pivot, Xavier ^c   Lochon, Isabelle ^b   Vo Van, Marie Louise ^d   Vauzelle, Françoise ^d   Lokiec, François ^a  

^a CENTRE RENÉ HUGUENIN   (France)

^b INSTITUT CLAUDIUS REGAUD   (France)

^c CENTRE ANTOINE LACASSAGNE   (France)

^d Ethypharm   (France)

Author keywords

Adults; Cisplatin; Plasma binding; Population pharmacokinetics

Indexed keywords

CISPLATIN; FLUOROURACIL; PLATINUM;

ABSORPTION; ADULT; AGED; ARTICLE; BODY SURFACE; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DEMOGRAPHY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; FEMALE; HUMAN; MALE; MALIGNANT NEOPLASTIC DISEASE; PHARMACOLOGICAL PARAMETERS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VALIDATION PROCESS;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC AGENTS; CISPLATIN; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; REFERENCE VALUES;

EID: 11244308198     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0852-8     Document Type: Article

References (13)

1. Beal SL, Sheiner LB (1998) NONMEM user's guide; NONMEM project group. University of California, San Francisco
2. Bonetti A, Franceschi T, Apostoli P, Messori A, Sperotto L, Getto GL, Molino A, Leone R (1995) Cisplatin pharmacokinetics using a five-day schedule during repeated courses of chemotherapy in germ cell tumors. Ther Drug Monit 17:25
3. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31
4. Griffiths H, Shelley MD, Fish RG (1987) A modified pharmacokinetic model for platinum disposition in ovarian cancer patients receiving cisplatin. Eur J Clin Pharmacol 33:67
5. Hanada K, Nishijima K, Ogata H, Atagi S, Kawahara M (2001) Population pharmacokinetic analysis of cisplatin and its metabolites in cancer patients: possible misinterpretation of covariates for pharmacokinetic parameters calculated from the concentrations of unchanged cisplatin, ultrafiltered platinum and total platinum. Jpn J Clin Oncol 31:179
6. Ihaka R, Gentleman R (1996) R: a language for data analysis and graphics. J Comput Graph Stat 5:299
7. Korst AE, van der Sterre ML, Gall HE, Fichtinger-Schepman AM, Vermorken JB, van der Vijgh WJ (1998) Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients. Clin Cancer Res 4:331
8. Le Roy AF, Wehling ML, Sponseller HL (1977) Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem Med 18:184
9. Murase M, Kondo K, Kodera Y, Kiriyama K, Akiyama S, Ito K, Yokoyama Y, Shirasaka T, Takagi H (1993) The clinical effect of chemotherapy with 5-FU and low-dose CDDP in patients with advanced gastric cancer. Jpn J Cancer Chemother 21:1025
10. Nagai N, Ogata H, Wada Y, Tsujino D, Someya K, Ohno T, Masuhara K, Tanaka Y, Takahashi H, Nagai H, Kato K, Koshiba Y, Igarashi T, Yokoyama A, Kinameri K, Kato T, Kurita Y (1998) Population pharmacokinetics and pharmacodynamics of cisplatin in patients with cancer: analysis with the NONMEM program. J Clin Pharmacol 38:1025
11. Parke J, Holford N, Charles B (1999) A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed 59:19
12. Schaake-Koning C, van den Bogaert W, Dalesio O, Festen J, Hoogenhout J, van Houtte P, Kirkpatrick A, Koolen M, Maat B, Nijs A (1994) Radiosensitization by cytotoxic drugs. The EORTC experience by the Radiotherapy and Lung Cancer Cooperative Groups. Lung Cancer 10:8263
13. Vermorken JB, van der Vijgh WJ, Klein I, Gall HE, van Groeningen CJ, Hart GA, Pinedo HM (1986) Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Clin Pharmacol Ther 39(2):136-144